J. Mater. Sci. Technol. ›› 2010, Vol. 26 ›› Issue (8): 754-758.

• Research Articles • 上一篇    下一篇

Biocompatibility of Surface-Modified Biphasic Calcium Phosphate/ Poly (L-Lactide) Biocomposite in vitro and in vivo

杨为中1,周大利2,尹光福3,顾建文4,李亚东4,张虎军4   

  1. 1. 四川大学材料科学与工程学院
    2.
    3. 四川大学
    4. 中国人民解放军成都军区总医院
  • 收稿日期:2009-07-21 修回日期:2009-11-17 出版日期:2010-08-28 发布日期:2010-08-23
  • 通讯作者: 杨为中

Biocompatibility of Surface-Modified Biphasic Calcium Phosphate/Poly-L-Lactide Biocomposite in vitro and in vivo

Weizhong Yang1), Guangfu Yin1), Dali Zhou1), Jianwen Gu2), Yadong Li2), Hujun Zhang2)   

  1. 1) College of Materials Science and Engineering, Sichuan University, Chengdu 610064, China
    2) Chengdu Military General Hospital, Chengdu 610083, China
  • Received:2009-07-21 Revised:2009-11-17 Online:2010-08-28 Published:2010-08-23
  • Contact: Jianwen Gu
  • Supported by:

    Doctoral Fund of Ministry of Education of China under grant No. 20060610024

RichHTML

1

PDF (PC)

849

摘要：

The biocompatibility of surface-modified biphasic calcium phosphate (mBCP)/ poly-L-Lactide (PLLA) biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Basing on the experiment results, surface-modified BCP/PLLA biocomposite is proved to have superior biocompatibility, which may be a promising bone repairing material.

Abstract:

The biocompatibility of surface-modified biphasic calcium phosphate (mBCP)/poly-L-Lactide (PLLA) biocomposite was investigated through a series of experiments in vitro and in vivo. Acute toxicity and short term systemic toxicity experiments revealed no toxicity of the materials. Hemolysis assay indicated the good blood compatibility of the composite. In cytotoxicity assay, L929 mouse fibroblasts could well differentiate and proliferate. Animal experiments in vivo were performed by implanting the materials into rabbits muscle for 8 weeks. The decreasing of inflammatory cells, the building of fibrous tissue layer as well as the growing of blood cells into materials indicated the nontoxicity of the composite. Based on the experiment results, surfacemodified BCP/PLLA biocomposite is proven to have superior biocompatibility, which would be a promising bone repairing material.

Key words: Biocompatibility, Biphasic calcium phosphate (BCP), Poly-L-Lactide (PLLA) biocomposite